Lantheus announces FDA review for new radioactive imaging agent

3 hours ago 1
Headquarters of US Food and Drug Administration (FDA)

Grandbrothers/iStock Editorial via Getty Images

Lantheus Holdings (NASDAQ:LNTH) announced on Wednesday that the U.S. Food and Drug Administration (FDA) accepted its marketing application for a new formulation of its F 18 PSMA radioactive imaging agent.

The New Drug Application filed by Lantheus’ (NASDAQ:LNTH) affiliate

Recommended For You

More Trending News

Read Entire Article